This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ben-Gurion University of the Negev Research and Development Authority. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Boaz Lerner: Innovator in Neurodegenerative Disease Prediction
Introduction
Boaz Lerner is a prominent inventor based in Mazkeret Batia, Israel. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patented technology. His work focuses on personalized medicine, aiming to improve patient outcomes by predicting disease progression.
Latest Patents
Lerner holds a patent for an "Integrated system and method for personalized stratification and prediction of neurodegenerative disease." This invention provides a comprehensive approach to identifying homogenous patient clusters from heterogeneous data. Each cluster is characterized by specific disease factors, which are utilized to predict the progression state and rate of neurodegenerative diseases for patients based on their unique profiles. He has 1 patent to his name.
Career Highlights
Boaz Lerner is affiliated with the Ben-Gurion University of the Negev Research and Development Authority. His role at this esteemed institution allows him to engage in cutting-edge research and collaborate with other experts in the field. His dedication to advancing medical science is evident in his innovative approaches to complex health issues.
Collaborations
Lerner has worked alongside notable colleagues, including Jonathan Gordon and Aviv Nahon. Their collaborative efforts contribute to the development of effective solutions for neurodegenerative diseases.
Conclusion
Boaz Lerner's work in the field of neurodegenerative disease prediction exemplifies the impact of innovation in healthcare. His patented technology represents a significant advancement in personalized medicine, offering hope for improved patient care and outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
